Popek-Marciniec, S.; Styk, W.; Wojcierowska-Litwin, M.; Szudy-Szczyrek, A.; Dudek, P.; Swiderska-Kolacz, G.; Czerwik-Marcinkowska, J.; Zmorzynski, S.
The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma. J. Clin. Med. 2023, 12, 2384.
https://doi.org/10.3390/jcm12062384
AMA Style
Popek-Marciniec S, Styk W, Wojcierowska-Litwin M, Szudy-Szczyrek A, Dudek P, Swiderska-Kolacz G, Czerwik-Marcinkowska J, Zmorzynski S.
The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma. Journal of Clinical Medicine. 2023; 12(6):2384.
https://doi.org/10.3390/jcm12062384
Chicago/Turabian Style
Popek-Marciniec, Sylwia, Wojciech Styk, Magdalena Wojcierowska-Litwin, Aneta Szudy-Szczyrek, Paul Dudek, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska, and Szymon Zmorzynski.
2023. "The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma" Journal of Clinical Medicine 12, no. 6: 2384.
https://doi.org/10.3390/jcm12062384
APA Style
Popek-Marciniec, S., Styk, W., Wojcierowska-Litwin, M., Szudy-Szczyrek, A., Dudek, P., Swiderska-Kolacz, G., Czerwik-Marcinkowska, J., & Zmorzynski, S.
(2023). The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma. Journal of Clinical Medicine, 12(6), 2384.
https://doi.org/10.3390/jcm12062384
